Logos Global Management LP
- SEC CIK
- 0001792126
- Latest filing
- Aug 14, 2026
Holdings in Q1 2021
Holdings as of Mar 31, 2021, filed May 17, 2021. Long positions only.
- Positions
- 53
- No 13F data for Q4 2020
- Portfolio value
- $1.02B
- No 13F data for Q4 2020
Livermore's 13F data starts with Q1 2021, so this quarter has no previous quarter to compare with and changes are not shown.
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ALXOAlx Oncology Holdings Inc | COM | 3,156,981 | $232.8M | 22.7% | – | – | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 3,743,875 | $124.2M | 12.1% | – | – | History |
| DSGNDesign Therapeutics, Inc. | COM | 2,732,501 | $81.7M | 8.0% | – | – | History |
| DYNDyne Therapeutics, Inc. | COM | 3,204,392 | $49.8M | 4.9% | – | – | History |
| TILInstil Bio, Inc. | COM | 1,846,850 | $46.3M | 4.5% | – | – | History |
| NKTXNkarta, Inc. | COM | 1,260,877 | $41.5M | 4.0% | – | – | History |
| FMTXForma Therapeutics Holdings, Inc. | SHS | 1,410,000 | $39.5M | 3.9% | – | – | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 1,056,812 | $34.3M | 3.4% | – | – | History |
| KNTEKinnate Biopharma Inc. | COM | 934,602 | $29.1M | 2.8% | – | – | History |
| RPTXRepare Therapeutics Inc. | COM | 900,000 | $27.6M | 2.7% | – | – | History |
| KRTXKaruna Therapeutics, Inc. | COM | 200,000 | $24.0M | 2.3% | – | – | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 800,000 | $23.9M | 2.3% | – | – | History |
| LONALeonaBio, Inc. | COM | 1,010,812 | $18.6M | 1.8% | – | – | History |
| BTAIQBioXcel Therapeutics, Inc. | COM | 400,000 | $17.3M | 1.7% | – | – | History |
| CGEMCullinan Therapeutics, Inc. | COM | 413,458 | $17.2M | 1.7% | – | – | History |
| CYTKCytokinetics Inc | COM NEW | 700,000 | $16.3M | 1.6% | – | – | History |
| TPTXTurning Point Therapeutics, Inc. | COM | 140,000 | $13.2M | 1.3% | – | – | History |
| COGTCogent Biosciences, Inc. | COM | 1,420,500 | $12.5M | 1.2% | – | – | History |
| IMAImageneBio, Inc. | COM | 419,853 | $11.9M | 1.2% | – | – | History |
| ALGSAligos Therapeutics, Inc. | COM | 476,547 | $10.8M | 1.1% | – | – | History |
| KYMRKymera Therapeutics, Inc. | COM | 260,920 | $10.1M | 1.0% | – | – | History |
| VINCVincerx Pharma, Inc. | COM NEW | 480,000 | $9.26M | 0.9% | – | – | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 250,000 | $9.21M | 0.9% | – | – | History |
| VRDNViridian Therapeutics, Inc. | COM | 550,000 | $9.19M | 0.9% | – | – | History |
| Aslan Pharmaceuticals Ltd04522R101 | ADS | 2,300,000 | $7.71M | 0.8% | – | – | – |
| ISEEIVERIC bio, Inc. | COM | 1,200,000 | $7.42M | 0.7% | – | – | History |
| KNSAKiniksa Pharmaceuticals International, plc | COM CL A | 400,000 | $7.40M | 0.7% | – | – | History |
| LABPLandos Biopharma, Inc. | COM | 734,000 | $7.07M | 0.7% | – | – | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 200,000 | $6.58M | 0.6% | – | – | History |
| HARPHarpoon Therapeutics, Inc. | COM | 300,000 | $6.28M | 0.6% | – | – | History |
| SPRYARS Pharmaceuticals, Inc. | COM | 125,000 | $5.45M | 0.5% | – | – | History |
| Therapeutics Acquisition Cor88339T103 | COM CL A | 500,000 | $5.25M | 0.5% | – | – | – |
| BOLTBolt Biotherapeutics, Inc. | COM | 150,000 | $4.94M | 0.5% | – | – | History |
| KZRKezar Life Sciences, Inc. | COM | 800,000 | $4.77M | 0.5% | – | – | History |
| ANNXAnnexon, Inc. | COM | 159,622 | $4.44M | 0.4% | – | – | History |
| VIRXViracta Therapeutics, Inc. | COM | 470,000 | $4.35M | 0.4% | – | – | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 112,928 | $4.18M | 0.4% | – | – | History |
| LRMRLarimar Therapeutics, Inc. | COM | 230,000 | $3.36M | 0.3% | – | – | History |
| OBIOOrchestra BioMed Holdings, Inc. | ORD SHS | 300,000 | $3.36M | 0.3% | – | – | History |
| HRMYHarmony Biosciences Holdings, Inc. | COM | 100,000 | $3.30M | 0.3% | – | – | History |
| RACBResearch Alliance Corp. II | COM CL A | 300,000 | $3.08M | 0.3% | – | – | History |
| LHDXLucira Health, Inc. | COM | 250,000 | $3.02M | 0.3% | – | – | History |
| FS Development Corp II30318F100 | COM CL A | 300,000 | $2.99M | 0.3% | – | – | – |
| DCPHDeciphera Pharmaceuticals, Inc. | COM | 62,000 | $2.78M | 0.3% | – | – | History |
| CNTBConnect Biopharma Holdings Ltd | ADS | 150,000 | $2.77M | 0.3% | – | – | History |
| EAREargo, Inc. | COM | 50,000 | $2.50M | 0.2% | – | – | History |
| ELDNEledon Pharmaceuticals, Inc. | COM | 224,071 | $2.40M | 0.2% | – | – | History |
| BCTG Acquisition Corp05492W103 | COM | 200,000 | $2.22M | 0.2% | – | – | – |
| PASGPassage BIO, Inc. | COM | 125,010 | $2.19M | 0.2% | – | – | History |
| ARYDARYA Sciences Acquisition Corp IV | CL A | 200,000 | $2.10M | 0.2% | – | – | History |
| MLTXMoonLake Immunotherapeutics | COM CL A | 200,000 | $2.04M | 0.2% | – | – | History |
| Nuvation Bio Inc.67080N119 | *W EXP 07/07/202 | 66,666 | $178.0K | <0.1% | – | – | – |
| Cerevel Therapeutics HLDNG I15678U102 | *W EXP 06/09/202 | 33,333 | $144.0K | <0.1% | – | – | – |